Results 41 to 50 of about 5,522,353 (395)

Data-driven prediction of adverse drug reactions induced by drug-drug interactions

BMC Pharmacology and Toxicology, 2017
Background The expanded use of multiple drugs has increased the occurrence of adverse drug reactions (ADRs) induced by drug-drug interactions (DDIs). However, such reactions are typically not observed in clinical drug-development studies because most of ...
Ruifeng Liu, Mohamed Diwan M. AbdulHameed, Kamal Kumar, Xueping Yu, Anders Wallqvist, Jaques Reifman   +5 more
doaj   +1 more source

A Review of Daclatasvir Drug–Drug Interactions [PDF]

Advances in Therapy, 2016
The treatment of hepatitis C virus (HCV) infection has been revolutionized in recent years by the development of direct-acting antiviral regimens that do not contain peginterferon (pegIFN) and/or ribavirin (RBV). While direct-acting antiviral-based regimens have been shown to be greatly superior to pegIFN/RBV-based regimens in terms of efficacy and ...
Shu-Pang Huang, Marc Bifano, Reena Wang, Hamza Kandoussi, Richard Bertz, Tushar Garimella, Timothy Eley, Xiaoli You   +7 more
openaire   +2 more sources

CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids [PDF]

, 2017
Purpose When codeine and tramadol are used for pain management, it is imperative that nurses are able to assess for potential drug-gene and drug-drug-gene interactions that could adversely impact drug metabolism and ultimately pain relief.
Broome, Marion E., Burke Draucker, Claire, Carpenter, Janet S., Holmes, Ann M., Knisely, Mitchell R., Skaar, Todd C., Von Ah, Diane   +6 more
core   +1 more source

Dephosphorylation of the HIV-1 restriction factor SAMHD1 is mediated by PP2A-B55α holoenzymes during mitotic exit

Nature Communications, 2018
SAMHD1 is a critical restriction factor for HIV-1 and its antiviral activity is regulated by T592 phosphorylation. Here, Schott et al. show that the phosphatase PP2A-B55α dephosphorylates SAMHD1 during mitotic exit, rendering it antivirally active in G1 ...
Kerstin Schott, Nina V. Fuchs, Rita Derua, Bijan Mahboubi, Esther Schnellbächer, Janna Seifried, Christiane Tondera, Heike Schmitz, Caitlin Shepard, Alberto Brandariz-Nuñez, Felipe Diaz-Griffero, Andreas Reuter, Baek Kim, Veerle Janssens, Renate König   +14 more
doaj   +1 more source

Predicting potential drug-drug interactions by integrating chemical, biological, phenotypic and network data

BMC Bioinformatics, 2017
Drug-drug interactions (DDIs) are one of the major concerns in drug discovery. Accurate prediction of potential DDIs can help to reduce unexpected interactions in the entire lifecycle of drugs, and are important for the drug safety surveillance.
Wen Zhang, Yanlin Chen, Feng Liu, Fei Luo, Gang Tian, Xiaohong Li   +5 more
semanticscholar   +1 more source

Drug–Drug–Gene Interactions in Cardiovascular Medicine

Pharmacogenomics and Personalized Medicine, 2022
Innocent G Asiimwe, Munir Pirmohamed The Wolfson Centre for Personalized Medicine, MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool ...
Asiimwe IG, Pirmohamed M
doaj  

Drug–Cannabinoid Interactions in Selected Therapeutics for Symptoms Associated with Epilepsy, Autism Spectrum Disorder, Cancer, Multiple Sclerosis, and Pain

Pharmaceuticals
Clinical practice entails a translation of research that assists in the use of scientific data and therapeutic evidence for the benefit of the patient. This review critically summarizes the potential impact of cannabinoids in conjunction with other drugs
Maria G. Campos, Maria China, Mariana Cláudio, Miguel Capinha, Rita Torres, Simão Oliveira, Ana Fortuna   +6 more
doaj   +1 more source

Magnitude of Drug–Drug Interactions in Special Populations

Pharmaceutics, 2022
Drug–drug interactions (DDIs) are one of the most frequent causes of adverse drug reactions or loss of treatment efficacy. The risk of DDIs increases with polypharmacy and is therefore of particular concern in individuals likely to present comorbidities (
Sara Bettonte, Mattia Berton, Catia Marzolini   +2 more
doaj   +1 more source

Drug-drug interaction

Jornal Brasileiro de Nefrologia, 2014
A doenca renal cronica (DRC), considerada a grande epidemia deste milenio, tem prevalencia media de 11% nos paises desenvolvidos. Infelizmente, no Brasil ainda nao dispomos de dados definitivos sobre a prevalencia da DRC, contudo, estudo realizado em amostra de 24.248 individuos adultos, utilizando o criterio de DRC baseado em duas determinacoes da ...
openaire   +3 more sources

Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017

Drug Metabolism And Disposition, 2018
Pharmacokinetic-based drug-drug interaction (DDI) data for drugs approved by the U.S. Food and Drug Administration in 2017 (N = 34) were analyzed using the University of Washington Drug Interaction Database. The mechanisms and clinical relevance of these
Jingjing Yu, I. Petrie, R. Levy, I. Ragueneau-Majlessi   +3 more
semanticscholar   +1 more source